反应详情

Following the procedure for the preparation of 1-cyclopentyl-6-[(3,4-trans)-4-methyl-1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one but substituting 1-cyclopentyl-6-[(3S,4S)-4-methylpyrrolidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-carbaldehyde provided the title compound. 400 MHz 1H NMR (CDCl3) δ 7.99 (s, 1H), 7.35 (s, 1H), 5.16-5.09 (m, 1H), 4.11-4.06 (m, 2H), 3.68 (d, J=13.3 Hz, 1H), 3.57 (d, J=13.3 Hz, 1H), 3.32 (t, J=8.7 Hz, 1H), 3.00 (d, J=9.9 Hz, 1H), 2.94-2.80 (m, 2H), 2.78-2.77 (m, 1H), 2.49-2.45 (m, 1H), 2.38-2.33 (m, 1H), 2.11-1.83 (m, 11H), 1.73-1.61 (m, 2H), 1.17 (d, J=7.1 Hz, 3H). MS: (M+H m/z=422.1).